Nanogen Shares Down 6.7 Percent on Lackluster Q4 Revenues, Widened Losses | GenomeWeb

NEW YORK, Feb. 24 (GenomeWeb News) - Shares in Nanogen were down 6.67 percent, or $.29, at $4.07 in late-afternoon trading after the company yesterday reported a 51-percent fall-off in fourth-quarter revenue and an 89-percent increase in its net losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.